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INTRODUCTION
Metformin is an effective anti-hyperglycemic agent and the 
drug of choice in patients with type 2 diabetes.1,2 It is well 
known that metformin has many beneficial effects on body 
weight, serum lipids, fibrinolysis, blood pressure, and endothe-
lial function.3-5 Furthermore, metformin can reduce diabetes-
related risks up to 32%, diabetes-related death up to 42%, and 
all-cause mortality up to 36%.3 However, metformin use is 
limited because of its potential adverse effects associated with 
lactic acidosis (LA), particularly in patients with reduced renal 
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Purpose: Metformin can reduce diabetes-related complications and mortality. However, its use is limited because of potential 
lactic acidosis-associated adverse effects, particularly in renal impairment patients. We aimed to investigate the association of 
metformin use with lactic acidosis and hyperlactatemia in patients with type 2 diabetes. 
Materials and Methods: This was a cross-sectional study from a tertiary university-affiliated medical center. A total of 1954 type 2 
diabetes patients were recruited in 2007–2011, and stratified according to the estimated glomerular filtration rate of 60 mL/
min/1.73 m2. Lactic acidosis was defined as plasma lactate levels >5 mmol/L and arterial pH <7.35.
Results: Metformin was used in 61.4% of the patients with type 2 diabetes mellitus. Plasma lactate levels were not different in the 
patients with and without metformin use. There was no difference in prevalence of hyperlactatemia and lactic acidosis between 
the patients with and without metformin use (18.9% vs. 18.7%, p=0.905 for hyperlactatemia and 2.8% vs. 3.3%, p=0.544 for lactic 
acidosis). Similar results were observed in the patients with estimated glomerular filtration rate <60 mL/min/1.73 m2. Most pa-
tients with lactic acidosis had at least one condition related to hypoxia or poor tissue perfusion. Multiple regression analysis indi-
cated no association between metformin use and lactic acidosis, whereas tissue hypoxia was an independent risk factor for lactic 
acidosis [odds ratio 4.603 (95% confidence interval, 1.327–15.965)]. 
Conclusion: Metformin use was not associated with hyperlactatemia or lactic acidosis in patients with type 2 diabetes.
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function.6 
The adverse effects of biguanides associated with LA have 
become a concern in clinical practice with the use of the first 
line biguanide, phenformin. Phenformin inhibits lactate oxi-
dation and increases lactate production.7,8 It has been reported 
that the incidence of phenformin-associated LA ranges between 
40 and 129 cases per 100000 patient-years.9,10 However, despite 
being a biguanide, metformin does not affect anaerobic lactate 
production.11 In fact, the incidence of LA is 10 to 20 times lower 
with the use of metformin than with that of phenformin.12 Fur-
thermore, several recent studies have suggested that the oc-
currence of LA with the use of metformin might be a coinci-
dence rather than a consequence. Scale and Harvey13 reported 
that LA was more common in patients with diabetes but was 
not more frequent in patients who had taken metformin. An-
other study has shown that the prevalence of LA is lower in pa-
tients with metformin therapy than those with sulfonylurea 
therapy (3.3 and 4.8 cases per 100000 patient-years, respective-
ly).14 Therefore, we aimed to investigate whether metformin 
use was associated with LA and hyperlactatemia in patients 
with type 2 diabetes.
MATERIALS AND METHODS
Patients and study design 
This was a cross-sectional study. In the present study, patients 
from the diabetes registry of the Severance Diabetes Center 
between January 2007 and December 2011 were retrospec-
tively evaluated. Of total 33758 diabetic patients, patients with 
type 1 diabetes, gestational diabetes, and patients whose lac-
tate levels were not reported were excluded. A total of 1954 pa-
tients aged ≥20 years and with type 2 diabetes were included in 
this study (Fig. 1). Medical history including medication use, 
history of operation, and underlying diseases was collected. 
Hyperlactatemia was defined as plasma lactate levels above 
the normal upper limit of 2.2 mmol/L. LA was defined as plas-
ma lactate levels of >5 mmol/L and arterial pH <7.35. All patients 
were stratified according to the use of metformin or the estimat-
ed glomerular filtration rate (eGFR) of 60 mL/min/1.73 m2. The 
metformin therapy group comprised patients who used met-
formin during the study period, and the non-metformin thera-
py group comprised subjects who did not use metformin in 
the year prior to data collection. This study was approved by 
the research ethics committee of the Severance Hospital, un-
der protocol No. 4-2014-0420.
Laboratory measurements 
Fasting and postprandial plasma glucose levels were mea-
sured using the glucose oxidase method on a Hitachi 747 au-
tomatic analyzer (Hitachi Instruments Service, Tokyo, Japan). 
Glycated hemoglobin (HbA1c) levels were measured using high-
performance liquid chromatography and a Variant II Turbo 
hemoglobin testing system (Bio-Rad Laboratories, Hercules, 
CA, USA). Plasma lactate levels were measured using the am-
perimetric electrode method. Arterial blood pH was analyzed 
in patients with increased lactate levels. Serum creatinine lev-
els were measured using the Jaffe method on a Hitachi 7600 
analyzer. The eGFR was calculated using the 4-variable Modi-
fication of Diet in Renal Disease study equation: eGFR=186.3× 
(creatinine)-1.154×age-0.203×0.742 (for women).15 Serum aspartate 
aminotransferase (AST) and alanine aminotransferase (ALT) 
levels were measured using the Internal Federation of Clinical 
Chemistry standardization without pyridoxal phosphate using 
a Hitachi 7600 analyzer. Among participants, we measured 
metformin concentration in those taking metformin and with 
reduced renal function (creatinine ≥1.5 mg/dL for men and 
≥1.4 mg/dL for women) (n=31). None of them had severe ill-
ness such as liver cirrhosis, acute coronary syndrome, malig-
nancy, acute infectious disease, and acute or severe renal fail-
ure (renal failure occurred within 7 days or serum creatinine 
≥3 mg/dL). Metformin concentration was measured by high-
performance liquid chromatography-tandem mass spectrom-
etry using a 1200 Series HPLC system (Agilent Technologies, 
Santa Clara, CA, USA) and API 4000TM mass spectrometer (AB 
Sciex, Framingham, MA, USA). The coefficient of variance ranged 
between 4.7% and 7.7%. 
Statistical analysis 
All continuous variables are shown as mean±standard devia-
tion or median (interquartile range) for data not normally dis-
tributed. Data were analyzed after stratification considering a 
threshold eGFR value of 60 mL/min/1.73 m2. Variable compari-
son between two groups was performed using Student’s t-test 
or chi-square test, as appropriate. The Mann-Whitney U test 
Fig. 1. Flow diagram of the study population.
n=1586
Hyperlactatemia (-)
n=368
Hyperlactatemia (+)
n=1104 excluded
; type 1 diabetes mellitus
n=689 excluded
; gestational diabetes
n=29850 excluded
; lactate levels were not reported
n=161 excluded
; <20 years old
n=310
Lactic acidosis (-)
n=58
Lactic acidosis (+)
n=33758
n=32654
n=31965
n=2115
n=1954
https://doi.org/10.3349/ymj.2017.58.2.312314
Metformin and Lactic Acidosis in Type 2 Diabetes
Ta
bl
e 
1. 
Ba
se
lin
e 
Ch
ar
ac
te
ris
tic
s o
f S
ub
je
ct
s A
cc
or
di
ng
 to
 th
e 
M
et
fo
rm
in
 U
se
 a
nd
 R
en
al
 Fu
nc
tio
n
Va
ria
bl
es
To
ta
l (
n=
19
54
)
eG
FR
 ≥
60
 m
L/
m
in
/1
.7
3 
m
2  (
n=
14
38
) 
eG
FR
 <
60
 m
L/
m
in
/1
.7
3 
m
2  (
n=
51
6)
N
o 
m
et
fo
rm
in
 u
se
 
(n
=7
54
)
M
et
fo
rm
in
 u
se
 
(n
=1
20
0)
p 
va
lu
e
N
o 
m
et
fo
rm
in
 u
se
 
(n
=5
84
)
M
et
fo
rm
in
 u
se
 
(n
=8
54
)
p 
va
lu
e
N
o 
m
et
fo
rm
in
 u
se
 
(n
=1
70
)
M
et
fo
rm
in
 u
se
 
(n
=3
46
)
p 
va
lu
e
Ag
e 
(yr
)
62
.3
±
11
.7
64
.6
±
11
.0
<0
.0
01
62
.4
±
11
.5
64
.0
±
11
.0
0.
00
8
62
.2
±
12
.4
65
.9
±
11
.0
<0
.0
01
Se
x (
w
om
en
, %
)
31
5 
(4
1.
8)
48
0 
(4
0.
0)
0.
23
2
23
8 
(4
0.
8)
32
8 
(3
8.
4)
0.
20
1
77
 (4
5.
3)
15
2 
(4
3.
9)
0.
42
1 
BM
I (
kg
/m
2 )
24
.3
±
3.
6
24
.1
±
3.
8
0.
20
8
24
.2
±
3.
5
24
.0
±
3.
7
0.
54
5
24
.8
±
3.
8
24
.3
±
3.
9
0.
18
2 
M
et
fo
rm
in
 d
os
e 
(m
g/
da
y)
−
10
00
 (5
00
–1
00
0)
−
10
00
 (5
00
–1
00
0)
−
10
00
 (5
00
–1
00
0)
La
ct
at
e 
(m
m
ol
/L
)
1.
2 
(0
.8
–1
.9
)
1.
1 
(0
.8
–1
.9
)
0.
05
0
1.
1 
(0
.8
–1
.8
)
1.
1 
(0
.8
–1
.8
)
0.
09
5
1.
4 
(0
.9
–2
.6
)
1.
2 
(0
.8
–2
.5
)
0.
08
7
Cr
 (m
g/
dL
)
1.
3±
1.
6
1.
2±
1.
1
0.
53
1
0.
8±
0.
2
0.
8±
0.
2
0.
50
8
2.
9±
2.
8
2.
3±
1.
7
0.
00
9 
eG
FR
 (m
L/
m
in
/1
.7
3 
m
2 )
81
.8
±
34
.0
79
.0
±
36
.5
0.
09
7
95
.4
±
24
.1
95
.8
±
28
.2
0.
74
5
35
.1
±
17
.6
37
.6
±
15
.5
0.
11
7 
Al
bu
m
in
ur
ia
 (m
g/
da
y)
26
.3
 (1
1.
9–
10
1.
2)
14
.0
 (0
–8
8.
6)
<0
.0
01
18
.8
 (9
.8
–6
0.
8)
9.
2 
(0
–3
5.
0)
<0
.0
01
71
.8
 (1
9.
9–
41
1.
7)
68
.3
 (1
3.
2–
44
2.
2)
0.
31
3
CO
2 (
m
m
ol
/L
)
21
.8
±
4.
6
21
.8
±
5.
7
0.
72
0
22
.5
±
4.
2
22
.6
±
5.
7
0.
79
2
19
.4
±
5.
3
19
.4
±
5.
1
0.
95
2 
AS
T 
(IU
/L
)
22
 (1
6–
36
)
23
 (1
6–
40
)
0.
18
6
23
 (1
7–
36
)
23
 (1
6–
39
)
0.
43
7
21
 (1
6–
41
)
24
 (1
6–
44
)
0.
24
3
AL
T 
(IU
/L
)
20
 (1
2–
33
)
19
 (1
3–
34
)
0.
55
4
20
 (1
3–
34
)
19
 (1
3–
33
)
0.
25
5
17
 (1
2–
31
)
19
 (1
2–
36
)
0.
45
1
FP
G 
(m
g/
dL
)
15
4.
6±
67
.4
14
8.
4±
65
.2
0.
05
3
15
2.
9±
62
.0
14
8.
1±
61
.3
0.
15
1
16
0.
1±
83
.4
14
9.
4±
75
.1
0.
16
1 
PP
G 
(m
g/
dL
)
22
0.
7±
97
.4
20
8.
7±
78
.0
0.
04
1
22
1.
7±
99
.3
20
6.
0±
77
.3
0.
02
2
21
7.
3±
91
.3
21
6.
1±
79
.7
0.
91
3 
Hb
A1
c (
%
)
7.
6±
4.
3
7.
4±
1.
6
0.
11
6
7.
7±
4.
9
7.
4±
1.
5
0.
10
0
7.
4±
1.
6
7.
4±
1.
8
0.
94
3 
To
ta
l c
ho
le
st
er
ol
 (m
g/
dL
)
15
6.
0±
49
.9
15
2.
9±
48
.7
0.
19
6
15
7.
4±
49
.2
15
5.
6±
49
.7
0.
51
0
15
1.
1±
52
.2
14
5.
6±
45
.2
0.
23
4 
Tr
ig
lyc
er
id
e 
(m
g/
dL
)
12
6 
(8
9–
17
1)
11
8 
(8
5–
16
4)
0.
14
7
12
6 
(8
8–
16
7)
11
8 
(8
4–
16
1)
0.
30
6
12
7 
(9
3–
20
1)
11
9 
(8
8–
16
9)
0.
26
8
HD
L-
ch
ol
es
te
ro
l (
m
g/
dL
)
41
.8
±
14
.6
42
.0
±
14
.0
0.
81
4
42
.8
±
13
.9
43
.1
±
14
.0
0.
79
2
39
.3
±
16
.0
39
.5
±
13
.6
0.
89
4 
LD
L-
ch
ol
es
te
ro
l (
m
g/
dL
)
95
.5
±
37
.1
90
.3
±
45
.8
0.
08
1
98
.3
±
37
.8
93
.6
±
50
.1
0.
20
7
87
.9
±
34
.2
82
.1
±
31
.2
0.
16
1 
AL
T, 
al
an
in
e 
am
in
ot
ra
ns
fe
ra
se
; A
ST
, a
sp
ar
ta
te
 a
m
in
ot
ra
ns
fe
ra
se
; B
M
I, 
bo
dy
 m
as
s 
in
de
x; 
CO
2, 
bi
ca
rb
on
at
e;
 C
r, 
cr
ea
tin
in
e;
 e
GF
R,
 e
st
im
at
ed
 g
lo
m
er
ul
ar
 fi
ltr
at
io
n 
ra
te
; F
PG
, f
as
tin
g 
pl
as
m
a 
gl
uc
os
e;
 H
bA
1c
, g
lyc
at
ed
 
he
m
og
lo
bi
n,
 H
DL
, h
ig
h 
de
ns
ity
 ch
ol
es
te
ro
l; 
LD
L, 
lo
w
 d
en
sit
y c
ho
le
st
er
ol
; P
PG
, p
os
tp
ra
nd
ia
l p
la
sm
a 
gl
uc
os
e.
 
Da
ta
 a
re
 m
ea
n±
SD
, m
ed
ia
n 
(in
te
rq
ua
rti
le
 ra
ng
e)
, o
r n
 (%
). 
315https://doi.org/10.3349/ymj.2017.58.2.312
Eun Young Lee, et al.
was used to compare two groups if variables were not normally 
distributed. Pearson’s correlation coefficient was used to as-
sess the association between metformin and lactate levels. 
Multiple logistic regression analysis was used to investigate the 
association between metformin use and LA after adjustment 
for confounding factors. Statistical analyses were performed 
using SPSS 18.0 software (SPSS Inc., Chicago, IL, USA), and a 
p value<0.05 was considered significant.
RESULTS
Baseline characteristic of the study subjects
Overall, 61.4% of the patients with diabetes were treated with 
metformin. Metformin therapy was more common in patients 
with eGFR level of <60 mL/min/1.73 m2 than in those with 
eGFR level ≥60 mL/min/1.73 m2 (67.1% vs. 59.4%, p=0.002). 
Table 1 shows the baseline characteristics of patients with and 
without metformin therapy. Among total participants, patients 
with metformin therapy were older but had lower albumin-
uria and postprandial glucose levels than those without metfor-
min therapy. There were no significant differences either in 
plasma lactate levels or in total bicarbonate (CO2) levels be-
tween the patients with and without metformin therapy [1.2 (in-
terquartile range, 0.8–1.9) mmol/L vs. 1.1 (interquartile range, 
0.8–1.9) mmol/L, p=0.050 for plasma lactate; 21.8±5.7 mmol/L 
vs. 21.8±4.6 mmol/L, p=0.720 for total CO2]. This was consistent-
ly observed in both eGFR subgroups. In addition, no significant 
correlation was found between metformin dose and plasma 
lactate levels (r=0.051, p=0.350) regardless of the eGFR levels. 
In 31 patients with reduced renal function, metformin con-
centration was measured. Median (interquartile range) met-
formin concentration was 0.97 (0.30–1.90) μg/mL and it in-
creased as metformin dose increased. However, there was no 
significant correlation between metformin concentration and 
plasma lactate levels (r=-0.018, p=0.924) or total CO2 (r=-0.042, 
p=0.833) levels (Supplementary Fig. 1 and 2, only online). 
 
Incidence of hyperlactatemia and lactic acidosis
Among the 1954 patients with diabetes, 18.8% of them pre-
sented with hyperlactatemia and 3.0% of them with LA (Table 
2). There was no significant difference in the prevalence of hy-
perlactatemia (18.9% vs. 18.7%, p=0.905) or LA (2.8% vs. 3.3%, 
p=0.544) between the patients with and without metformin 
therapy. Regardless of eGFR levels, there was no significant 
difference in the prevalence of hyperlactatemia or LA. Al-
though not significant, the prevalence of LA in patients with 
metformin therapy was lower than that in patients without 
metformin therapy, even in the patient subgroup with eGFR 
<60 ml/min/1.73 m2.
 
Comparison of subjects with hyperlactatemia 
according to the development of lactic acidosis
We further evaluated patients with hyperlactatemia according 
to the occurrence of LA (Table 3). LA occurred in 16.0% of the 
patients with hyperlactatemia. The mortality rates of patients 
with hyperlactatemia and LA were 15.2% and 39.0%, respec-
tively. Compared with patients with hyperlactatemia but with-
Table 2. Prevalence of Hyperlactatemia and Lactic Acidosis in Patients with Type 2 Diabetes According to Metformin Use
Stratification by eGFR Total, n (%) No metformin use, n (%) Metformin use, n (%) p value
Total 1954 754 1200
Hyperlactatemia 368 (18.8) 141 (18.7) 227 (18.9) 0.905 
Lactic acidosis 58 (3.0) 25 (3.3) 33 (2.8) 0.544 
eGFR ≥60 mL/min/1.73 m2 1438 584 854
Hyperlactatemia 225 (15.6) 93 (15.9) 132 (15.5) 0.810 
Lactic acidosis 22 (1.5) 12 (2.1) 10 (1.2) 0.180 
eGFR <60 mL/min/1.73 m2 516 170 346
Hyperlactatemia 143 (27.7) 48 (28.2) 95 (27.5) 0.853 
Lactic acidosis 36 (7.0) 13 (7.6) 23 (6.9) 0.769 
eGFR, estimated glomerular filtration rate.
Fig. 2. Odds ratio for the development of lactic acidosis in subgroup 
with hyperlactatemia. The odds ratio of eGFR was expressed as an in-
creased risk per 10 mL/min/1.73 m2 increase of eGFR. ALT, alanine ami-
notransferase; BMI, body mass index; CI, confidence interval; DM, dia-
betes mellitus; eGFR, estimated glomerular filtration rate; HbA1c, 
glycated hemoglobin.
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0.957 (0.415–2.210)Metformin
4.603 (1.327–15.965)
1 2 3 4 5 16
Underlying causes
https://doi.org/10.3349/ymj.2017.58.2.312316
Metformin and Lactic Acidosis in Type 2 Diabetes
out LA, patients with hyperlactatemia and LA had higher plas-
ma lactate levels [10.4 (interquartile range, 6.4–13.3) mmol/L 
vs. 3.3 (interquartile range, 2.7–4.3) mmol/L, p<0.001], but 
lower arterial pH (7.2±0.1 vs. 7.4±0.1, p<0.001) and total CO2 
levels (14.2±5.3 mmol/L vs. 20.5±4.3 mmol/L, p<0.001). The 
eGFR level significantly decreased in patients with LA in com-
parison with those without LA (53.5±37.3 mL/min/1.73 m2 vs. 
71.9±32.6 mL/min/1.73 m2, p<0.001). Liver enzymes signifi-
cantly increased in patients with LA compared with those with-
out LA [92 (interquartile range, 28–238) IU/L vs. 25 (interquar-
tile range, 18–45), p<0.001 for AST and 49 (interquartile range, 
20–137) IU/L vs. 22 (interquartile range, 15–39) IU/L, p<0.001 for 
ALT]. There was no significant difference in the number of pa-
tients with metformin therapy or in the metformin dose be-
Table 3. Biochemical Profile of Subjects with Hyperlactatemia According to the Occurrence of Lactic Acidosis
Variables
Hyperlactatemia (n=368)
p value
No lactic acidosis (n=310) Lactic acidosis (n=58)
Age (yr) 64.5±11.2 63.5±13.2 0.556 
Sex (women, %) 142 (45.8) 18 (31.0) 0.023 
BMI (kg/m2) 24.0±4.0 23.9±3.0 0.777 
Duration of diabetes (yr) 2 (0–9) 3 (1–8) 0.193
Metformin dose (mg/day) 500 (0–1000) 500 (0–1000) 0.750
Lactate (mmol/L) 3.3 (2.7–4.3) 10.4 (6.4–13.3) <0.001
Cr (mg/dL) 1.3±1.1 2.1±1.6 0.001 
eGFR (mL/min/1.73 m2) 71.9±32.6 53.5±37.3 <0.001
Albuminuria (mg/day) 17.4 (0–96.0) 33.0 (8.1–227.4) 0.065
Arterial pH 7.4±0.1 7.2±0.1 <0.001
CO2 (mmol/L) 20.5±4.3 14.2±5.3 <0.001
AST (IU/L) 25 (18–45) 92 (28–238) <0.001
ALT (IU/L) 22 (15–39) 49 (20–137) <0.001
FPG (mg/dL) 168.7±95.4 171.5±76.5 0.836 
PPG (mg/dL) 224.7±88.4 259.5±94.7 0.065 
HbA1c (%) 7.3±1.6 7.5±1.8 0.404 
Total cholesterol (mg/dL) 157.5±52.2 134.4±56.9 0.003 
Triglyceride (mg/dL) 130 (94–169) 123 (62–169) 0.345
HDL-cholesterol (mg/dL) 42.0±14.4 36.0±13.3 0.026 
LDL-cholesterol (mg/dL) 95.7±37.3 85.3±39.8 0.146 
Insulin (n, %) 105 (33.9) 26 (44.8) 0.110
Metformin use (n, %) 194 (62.6) 33 (56.9) 0.414 
Sulfonylurea (n, %) 81 (26.1) 16 (27.6) 0.817
Other OHA (n, %) 37 (11.9) 9 (15.5) 0.449
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CO2, bicarbonate; Cr, creatinine; eGFR, estimated glomerular filtration 
rate; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin, HDL, high density lipoprotein; LDL, low density lipoprotein; OHA, oral hypoglycemic agent; PPG, 
postprandial plasma glucose.
Data are mean±SD, median (interquartile range), or n (%). 
Table 4. Underlying Causes According to the Lactic Acidosis
Underlying causes No lactic acidosis, n (%) Lactic acidosis, n (%) p value
Sepsis 43 (13.9) 18 (30.5) 0.002
Infection 138 (44.7) 26 (44.1) 0.933
Myocardial infarction* 6 (1.9) 2 (3.4) 0.376
Heart failure* 14 (4.5) 2 (3.4) 0.512
Hypoxia 39 (12.6) 6 (10.3) 0.598
Shock 56 (18.1) 21 (35.6) 0.003
Liver cirrhosis 15 (4.9) 12 (20.3) <0.001
Grand mal seizure* 1 (0.3) 2 (3.4) 0.068
Bleeding 36 (11.7) 17 (28.8) 0.001
*Fisher’s exact test.     
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tration with lactate levels in patients with chronic kidney dis-
ease but without LA.22 In accordance with our results, this study 
demonstrated no correlation of lactate levels with metformin 
concentration. In Asian population with type 2 diabetes, an ob-
servational study showed that the mean plasma lactate level 
was not associated with total daily dose of metformin.25 
In the present study, most patients with LA had at least one 
condition that could result in tissue hypoxia. In accordance 
with our results, previous case series of metformin-associated 
LA have demonstrated that all patients except one case had 
clinical shock or tissue hypoxia.24,26 In the largest study of met-
formin-treated patients with LA (n=49), all patients had at least 
one disease that could lead to tissue hypoxia, such as cardio-
pulmonary failure, sepsis, or hemorrhage.20 Among the patients 
treated with other hypoglycemic agents except metformin, se-
vere medical condition causing tissue hypoxia has been con-
sistently observed in all patients with LA.27 Taken together, 
previous studies suggest that underlying disease associated 
with tissue hypoxia rather than metformin use is linked to LA 
in diabetic patients. In addition to confirming the previous ob-
servation, we also found that this condition had an indepen-
dent association with LA, even after adjustment for possible 
confounders.
It is one of strengths of our study that we measured plasma 
lactate and bicarbonate levels in a relatively large sample 
(n=1954). Previous studies with a large sample size usually used 
the diagnosis of acidosis or LA from the medical record. We 
also adjusted possible confounding factors to evaluate the as-
sociation of metformin use and the presence of LA. Although a 
small number of participants (n=31), measurement of metfor-
min concentration is an another strength of this study. To the 
best of our knowledge, this is the largest study of metformin-
treated patients with LA in Asian population. However, there 
are several limitations. The retrospective and cross-sectional 
nature of the study did not allow us to accurately determine the 
causal relationship between metformin use and LA. Second, 
we could not adjust the severity of underlying diseases. Lastly, 
our results could not be generalized to other population. 
In conclusion, we demonstrated herein that there is no asso-
ciation between metformin use and the risk of LA or elevated 
lactate concentration in type 2 diabetes, suggesting that metfor-
min might be a bystander rather than the cause of LA. Further 
prospective studies are needed to elucidate the direct role of 
metformin on the development of LA in subjects with type 2 
diabetes.
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